Close

DENV-4 NS3

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The DENV NS3 is a serine protease, as well as an RNA helicase and RTPase/NTPase. The protease domain consists of six β-strands arranged into two β-barrels formed by residues 1–180 of the protein. The catalytic triad (His-51, Asp-75 and Ser-135), is found between these two β-barrels, and activity is dependent on the presence of the NS2B cofactor. This cofactor wraps around the NS3 protease domain and becomes part of the active site. The remaining NS3 residues (180–618), form the three subdomains of the DENV helicase. A six-stranded parallel β-sheet surrounded by four α-helices make up subdomains I and II, and subdomain III is composed of 4 α-helices surrounded by three shorter α-helices and two antiparallel β-strands.
  • TCR Cell Products

Loading...
  • Cell Type:
  • Target:
  • HLA:
  • Epitope:
CAT Product Name Cell Type Target HLA Epitope Inquiry & Datasheet
TCRJ-CQ266 Anti-DENV-4 NS3 (VIGLYGNGV) T Cell Receptor (clone JK4), Jurkat Cell Line T lymphocyte DENV-4 NS3 HLA-DR15 VIGLYGNGV   Add to Cart   Datasheet
TCRJ-CQ267 Anti-DENV-4 NS3 (VIGLYGNGV) T Cell Receptor (clone JK43), Jurkat Cell Line T lymphocyte DENV-4 NS3 HLA-DR15 VIGLYGNGV   Add to Cart   Datasheet
XS-0623-ZP134 Anti-DENV-4 NS3 TCR-NK Cells TCR-NK DENV-4 NS3   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.